Today’s guest is Vin Narayanan, the Vice President of Strategy for KingsCrowd and Early Investing. The two discuss why the regulation crowdfunding market is particularly well-suited for biotech and pharmacy startups — and why that’s great news for investors.
Wall Street has Morningstar, S&P, and Bloomberg
The equity crowdfunding market has KingsCrowd.
